BROSSARD, Quebec, May 08, 2019 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK), (DGNOD), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today that further to the share consolidation of one (1) new common share for each ten (10) pre-consolidation common shares, which became effective April 24, 2019, the symbol used on the OTCQB has been changed from DGNOF to DGNOD. The symbol used on the TSX Venture remains ADK.
DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time and has been cleared for commercialization by several regulatory authorities such as Health Canada, the U.S. Food and Drug Administration and the European Union.
Additional information on DIAGNOS is available at www.diagnos.com and www.sedar.com.
OTC Markets Group Inc. (OTCM) operates the OTCQX® Best Market, the OTCQB® Venture Market, and the Pink® Open Market for 10,000 U.S. and global securities. Through OTC Link® ATS, it connects a diverse network of broker-dealers that provide liquidity and execution services. It enables investors to easily trade through the broker of their choice and empower companies to improve the quality of information available for investors.
Additional information on OTCQB is available at www.otcmarkets.com/about/press-center.
For further information, please contact:
|Mr. André Larente, President|
|Tel: 450-678-8882 ext. 224|
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.